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Abstract
In the last two decades, new discoveries concerning on breast cancer have 
contributed to important changes on its classification, from purely morphologic to 
molecular embased, to establish better correlation with clinicopathologic features. 
The classification in molecular subtypes, based on hormonal receptor and HER-2 
status, have been remarkable not only for its more accurated clinical correlations, 
but also for its easy applicability in diagnostic routine, better replication of tumor 
microenvironment through the selection of paraffinized tumor amounts and 
cost-effectiveness of the detection method, the immunohistochemistry. Hence, 
this classification may predict the breast cancer prognosis and became an impor-
tant target for therapy with hormonal and HER-2 antagonist drugs. Other study 
models, like cancer-stem cell hypothesis and immunological aspects of human 
cancer, have brought new emerging ideas regarding on molecular pathways and 
accurated prognostic preditions. Putative stem-cell markers and PD-1/PDL-1, have 
highlighted among several emerging molecular markers because of the bad cancer 
prognosis determinated by stem-cell markers expression and for emerging new 
drugs with selective action to PD-1/PDL-1, with promising results. The therapy of 
breast cancer have became diverse, target directed and personalized, in order to 
take in consideration the clinicopathologic cancer aspects, molecular tumor profile 
and clinical status of the patient.
Keywords: breast cancer, target therapy, molecular markers, prognostic markers, 
immunomarkers, cancer stem-cell
1. Introduction
Breast cancer is the one of the three most frequent human neoplastic disease 
worldwide and is the most common female cancer, remaining with considerable 
impact on general mortality. Worldwide, in the last 10 years, the incidence is 
 growing up, with approximately 2.1 million of new cases per year and estimated 
mortality of 15%, at about 300.000 per year [1, 2].
Breast cancer remains as an heterogeneous group of disease from the point 
of view of biological behavior, therapeutic issues and prognostic features, deter-
mining different tracks of overall and free of disease survivals [3, 4]. Thus, the 
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clinicopathologic classification of breast cancer has been challenging over the last 
years, since the isolated simple morphologic classification of the tumor on histol-
ogy examination is not necessarily related to the precise biologic behavior of the 
disease [5, 6].
In this way, especially over the last two decades, important researches revealing 
novel molecular markers expressed by cancer cells has been published in the lit-
erature. The new discoveries have improved the breast cancer classification, which 
has been progressed from a purely morphologic classification, based on histologic 
patterns, to a molecular classification, based on expression of oncoproteins and 
hormonal receptors, detected mainly by immunohistochemical techniques, in 
paraffin-embedded tumoral specimens [6, 7].
The novel molecular classification of breast cancer seems to exhibit more 
 accurated correlation to the clinicopathological aspects of the tumor, as proliferative 
index, invasiveness and potential to metastatic spread. Furthermore, some of these 
molecular markers allowed the development of new drugs with specific actions on 
populations of cancer cells with specific genes alterations, improving considerably 
the therapeutic, prognostic and survival issues [7].
Instead of the recent advances on new therapeutic protocols under a new 
molecular perspective, early breast cancer on clinicopathological classification 
still remains the single one potencially curative [8]. The management of advanced 
clinicopathologic stage tumors and some established molecular groups of cancer, 
especially the ‘triple negative’ disease, remains with lacks of consensus. Anyway, 
the molecular markers have just improved the pathophysiology pathways knowl-
edge, with potential future development of promising new drugs for target therapy 
of breast cancer [8–10] .
2.  The molecular subtypes of breast cancer of clinicopathologic 
importance
In the beginning of the 21st century, breast cancer was classified mainly on 
 histologic basis. The WHO current histologic classification of breast cancer is 
demonstrated in Table 1. Photomicrographies of the most frequent histologic 
subtypes of invasive breast cancer are represented on Figure 1. The hormonal status 
receptors (estrogen and progesterone) expression by the neoplastic cells was just 
evaluated by immunohistochemistry on paraffin-embedded specimens of tumor 
(core needle biopsy or the surgical excision specimen) [6, 7] .
Breast cancer is known for its heterogeneous behavior [3, 4]. The histologic 
classification has been satisfactory for malignancy determination [6]. Though, the 
clinical division based on hormonal status was not enough for accurate prediction 
of the prognosis and of clinical response to the therapy [5]. Thus, until the last 
decade of 20th century, the clinical treatment of breast cancer was based on unespe-
cific chemotherapy and hormonal therapy with drugs like tamoxifen, a known 
hormonal receptor antagonist [12].
The hormone positive breast cancer is more “differentiated” than the negative 
one, as the cancer cells maintain the epithelial original cell feature of hormonal 
receptor expression and, therefore, the hormonal antagonist drugs are effective 
against these tumors [8]. On the other hand, the approaching of hormonal negative 
cancers were variable, since it was forming a kindly heterogeneous group, with 
different aggressiveness potentials, imprecise therapeutic response and doubtful 
prognosis [6, 8, 10].
In the first decade of the current century, it was emerged a promising classifica-
tion of breast cancer, proposing a division of the disease in 3 molecular subtypes: 
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WHO classification of epithelial breast tumors (5th edition, 2019)
Benign epithelial proliferations and precursors
• Usual ductal hyperplasia
• Columnar cell lesions, including flat epithelial 
atypia
• Atypical ductal hyperplasia
















• Ductal carcinoma in situ, papillary
• Encapsulated papillary carcinoma
• Encapsulated papillary carcinoma with invasion
• Solid papillary carcinoma in situ
• Solid papillary carcinoma with invasion
• Intraductal papillary adenocarcinoma with 
invasion
Non-invasive lobular neoplasia
• Atypical lobular hyperplasia
• Lobular carcinoma in situ NOS
 ○ Classic lobular carcinoma in situ
 ○ Florid lobular carcinoma in situ
 ○ Lobular carcinoma in situ, pleomorphic
Ductal carcinoma in situ (DCIS)
• Intraductal carcinoma, non-infiltrating, NOS
 ○ DCIS of low nuclear grade
 ○ DCIS of intermediate nuclear grade
 ○ DCIS of high nuclear grade
Invasive breast carcinoma





• Lobular carcinoma NOS
• Tubular carcinoma
• Cribriform carcinoma NOS
• Mucinous adenocarcinoma
• Mucinous cystadenocarcinoma NOS
• Invasive micropapillary carcinoma of breast
• Apocrine adenocarcinoma
• Metaplastic carcinoma NOS
Rare and salivary gland-type tumors
• Acinar cell carcinoma
• Adenoid cystic carcinoma
 ○ Classic adenoid cystic carcinoma
 ○ Solid-basaloid adenoid cystic carcinoma





• Tall cell carcinoma with reverse polarity
Neuroendocrine neoplasms
• Neuroendocrine tumor NOS
• Neuroendocrine tumor, grade 1
• Neuroendocrine tumor, grade 2
• Neuroendocrine carcinoma NOS
• Neuroendocrine carcinoma small cell
• Neuroendocrine carcinoma large cell
Table 1. 
Current histologic (morphologic) classification of epithelial breast tumors (WHO, 2019, 5th edition). This 
classification considers the tumors histologic patterns of tumors. The most common histologic breast cancer 
subtype is the infiltrating duct carcinoma NOS (or invasive ductal carcinoma non-special type), accounting 
for 65–80% of all breast cancers. Invasive lobular carcinoma corresponds to around 5% of all breast 
malignancies.
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luminal, HER-2 overexpressed and “triple negative” (Table 2). This new classifica-
tion has demonstrated better correlation with the breast cancer behavior. Thus, it 
was adopted on diagnostic routine of breast cancer. Since this study was published, 
besides of evaluate the histologic patterns and report the pathologic tumor stage, 
the pathologist has been required to determine the molecular cancer profile, which 
has became indispensable to therapy planning [12, 13].
The luminal subtype cancer is the hormonal positive tumors. This kind of cancer 
is frequently well or moderately differentiated on histology, formed by lower grades 
of cells, with lower proliferative index, which is evaluated by antibody Ki-67/MIB-1 
on immunohistochemistry. The majority of breast cancers are classified as this 
subtype (Figure 2). Eventually, luminal cancer can overexpress or amplify at the 
same time the protein called human epithelial growth factor receptor 2 (HER-2), 
codified by the oncogen ERBB2 [14, 15].
ERBB2 is a oncogen localized in chromosome 17, which codifies the HER-2 
protein, a type I transmembrane protein with an extracellular and an intracellular 
domains, activating signaling pathways from extracellular signals. In last instance, 
the overexpression/amplification of HER-2 overactivates the intracellular protein 
kinases, dysregulating the cell cycle, disrupting the cell adhesion and cell polarity 
and promoting the invasive phenotype [16].
Figure 1. 
Photomicrographies of hematoxylin & eosin (H&E) slides illustrating the most frequent histologic subtypes 
of infiltrating (invasive) breast cancer. (A) Infiltrating duct carcinoma (Invasive ductal carcinoma NOS) 
is the most frequent histologic subtype of breast cancer (nearly 75–80% of all invasive breast cancer), 
constituted of cohesive cancer cells forming infiltrative ductal and ribbons structures (4×); (B) Lobular 
invasive carcinoma is the second most frequent invasive breast cancer (5–15% of all invasive breast cancer), 
composed of infiltrating cancer cells with diffuse single-file pattern (10×). In this subtype, the cancer cells 
lose the cohesion (e-cadherin, an immunomarker important for cell adhesion evaluation, is negative on 
immunohistochemistry); (C) Mucinous carcinoma represents approximately 2% of breast invasive cancer, 
composed of groups of cancer cells outling ductal structures, immersed in mucin pools, with delicate fibrous 
strands containing capilaries (10×); (D) Tubular carcinoma represents around 2% of invasive breast cancer, 
composed of haphazard arrangement of small well-differentiated duct structures, forming tubules (4×). The 
other listed invasive breast cancers are uncommon, with each one histologic subtype representing 1% or less 
( figures extracted from [11]).
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The breast cancer classified as HER-2 subtype is necessarily negative for hor-
monal receptors and is featured by overexpression or amplification of HER-2. This 
subtype is frequently less differentiated than the luminal ones on histology, con-
stituted by high grades of cancer cells, with high proliferative index. The presence 
of elevated concentration of intratumoral lymphocytes (TIL) is not an uncommon 
finding in these tumors [17].




 ○ Luminal B1
 ○ Luminal B2
Hormone receptors positive (ER+ and/or PR+)
• with Ki-67 < 14% of cancer cells
• with Ki-67 > 14% of cancer cells
 ○ HER-2 negative




HER-2 overexpressed Hormone receptors negative (ER and PR negative) 
and HER-2 positive
10–20%




Molecular subtypes of breast carcinoma. The reported absolute incidences of each molecular subtype of breast 
carcinoma are variable among several studies.
Figure 2. 
Photomicrographies of immunohistochemical assessment of invasive breast cancer hormonal expression, in an 
example of infiltrating duct carcinoma (Invasive ductal carcinoma NOS, WHO 2019), which is the most frequent 
histologic subtype of breast cancer, constituted by ductal and ribbons structures of cancer cells infiltrating the 
breast stroma (A). Any kind of nuclear positivity of estrogen receptor (B) and progesterone receptor (C) allows 
to consider the tumor as positive to hormonal receptor on immunohistochemistry, even when rare cells are positive 
(C). The hormonal receptors positivities on immunohistochemistry are evaluated for intensity (mild, moderate 
or strong) and percentages of positive cells (0–100%). Examples of mild positivity (black arrow, C), moderate 
positivity (red arrow, B) and strong positivity (green arrow, C). Ki-67/ MIB-1 assesses the tumor proliferative 
index (D), its positivity is nuclear and is expressed in percentages of positive cells (0–100%).
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Figure 3. 
(a) Photomicrographies of immunohistochemical assessment of HER-2 expression status by tumoral cells 
in histologic paraffinized specimen of breast cancer. Score 0 (negative): none tumoral cell is labeled. Score 
1+ (negative): incomplete positivity with low intensity in part of tumoral cells. Score 2+ (equivocal): 
complete positivity with low intensity in majority of tumoral cells. Score 3+ (positive): complete positivity 
with strong intensity in majority of tumoral cells. (b) Photomicrographies of amplification of HER-2 gene 
performed through fluorescence in situ hibridization (FISH) in a HER-2-overexpressed breast carcinoma 
on immunohistochemistry (Score 3+, E). HER-2 gene copies are the orange signals (B) and chromosome 17 
centromeres (CEP17) are the green signals (C). The signals of HER-2 gene and CEP17 are present in tumoral 
cell nuclei (blue, A and D). CEP17 is an internal control on the same chromosome to compare with HER-2 
signals in tumoral cell nucleus. According to American Society of Clinical Oncology/College of American 
Pathologists (ASCO-CAP) guidelines, a HER-2/CEP17 ratio > 2.0 defines a positive result for amplification of 
HER-2 gene. If HER-2/CEP17 ratio is < 2.0, an average HER-2 copy number > 6.0 signals/cell defines a positive 
result for amplification of HER-2 gene, an average HER-2 copy number < 4.0 signals/cell defines a negative 
result for amplification of HER-2 gene and an average HER-2 copy number > 4.0 and < 6.0 signals/cell defines 
an equivocal result for amplification of HER-2 gene (extracted from [20]).
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This new receptor was one of the pioneers for target therapy in molecular era of 
breast cancer approaching, as it was developed a new class of drug, called trastu-
zumab, with selective action against the cancer cells overexpressing/amplifying 
HER-2. Besides the HER-2 subtype tumors, this drug is also recommended for the 
luminal ones with positive status for HER-2 [18, 19].
The status of HER-2 expression is analyzed through immunohistochemistry of 
paraffin-embedded specimens of the breast cancer (Figure 3a). The tumor is consid-
ered negative for HER-2 if it is not labeled (score zero) or the cell membrane is par-
tially labelled for the HER-2 antibody (score 1+). The tumor is positive for HER-2 if all 
the cell membranes outlines are strongly labeled for this antibody (score 3+). Finally, 
in part of the cases, the HER-2 antibody can label totally the cancer cell membrane, 
but with low intensity or can label partially the cell membrane with high intensity. In 
these situations, the HER-2 status is considered equivocal (score 2+). The confirma-
tion of overexpression/amplification must be evaluated through fluorescence “in situ” 
hybridization (FISH) (Figure 3b) [21, 22].
The “triple negative” breast cancer is negative for hormonal receptors and HER-2. 
It is the less differentiated tumor subtype on histology, formed by highest grades 
cancer cells, with highest proliferative index, presenting the worst prognosis among 
the 3 molecular subtypes. This tumor still does not present an specific therapy, which 
is chosen depending on the clinicopathological stage. In metastatic disease, the 
treatment focuses on quality of life and palliation. In “triple negative” tumors, the 
evaluation of BRCA status is mandatory [8, 21].
3.  Germline mutations of BRCA-1/BRCA-2 genes: increased risk of 
breast cancer development during the life
Identified in 1994, BRCA-1/BRCA-2 are tumoral suppressor genes, respectively 
located in chromosome 17 and 13. Mutations of these genes are related to hereditary 
breast cancer, estimated in 5–10% of all breast malignancies. BRCA-1/BRCA-2 play a 
central role in DNA repair [23, 24]. Mutations of these genes increase the susceptibil-
ity for DNA damages. “Triple negative” subtypes carry more frequently mutations 
of BRCA-1 and mutations of BRCA-2 increase the risk for luminal subtypes of breast 
cancer. HER-2 overexpression is inversely correlated to BRCA mutations [24, 25].
It was observed in some studies that “triple negative” breast cancers with BRCA 
mutations present more chemosensitivity than the ones without BRCA mutations. 
Chemotherapy with DNA-damaging drugs, like the alkylating agents and anthracy-
cline, can prolong the free of disease survival for tumors of triple negative phe-
notypes. This found is expected, since BRCA mutation prejudices the DNA repair 
and, consequently, increase the sensibility to DNA damages of cancer cells by these 
drugs. Neither therapeutic response nor free of disease survival of luminal subtypes 
of breast cancer seems to be influenced by BRCA mutations [8, 24, 26].
Regarding on prognosis, multiples studies present conflicting results. The 
prognosis depends on tumor features, especially the molecular subtypes and the 
clinicopathologic stage. The predictive value depends on the administrated therapy. 
Thus, BRCA-1 mutated breast cancer probably present worse prognosis than the 
BRCA-2 mutated ones, since BRCA-1 mutated tumors are mainly of “triple nega-
tive” phenotype, therefore intrinsically more aggressive than the luminal subtypes 
harboring BRCA-2 mutations [24, 27].
The tumoral suppressor proteins codified by BRCA-1/BRCA-2 act on homolo-
gous recombination repair of double stranded DNA breaks. Homologous recom-
bination mechanism protect the integrity of genome in proliferating cells. BRCA-1 
recognize DNA damage and recruit DNA repair proteins. BRCA-2 mediates the 
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recruitment of another protein, called RAD51, to double stranded DNA breaks, 
allowing for homologous recombination repair [24, 28].
In BRCA-mutant breast tumors, the base excision repair pathway is important 
for cancer cell survival, in response to single stranded DNA breaks. Polyadenosine 
diphosphate-ribose (PARP) is a family of DNA repair enzymes, playing a key role 
in base excision repair mechanism. These enzymes are recruited to the site of DNA 
damage and add ADP-ribose to target nuclear proteins, causing post-translational 
modifications and restarting stalled DNA replication. BRCA-mutant breast cancer 
presents deficiency of homologous recombination repair, with overactivated PARP, 
leading the cancer cell to avoid apoptosis [24, 26, 28].
The inhibition of PARP cause persistance of single stranded break, resulting in 
stalled replication and double strand breaks. This mechanism leads to accumula-
tion of DNA damage, causing cell cycle arrest and apoptosis. The PARP inhibitors 
form an emerging class of drugs, which have been recommended to chemotherapy 
for BRCA-mutant breast cancer and empirically for metastatic breast cancer, with 
promising results [24, 25, 28].
4. Cancer stem-cell hypothesis: impact in breast cancer prognosis
In the last two decades, experimental evidences in several studies of neoplastic 
tissues have revealed a population of cancer cell with properties of self-renewal, dif-
ferentiation to multiple lineages ability and low proliferative index. These proper-
ties have been considered cancer stem-cell like features and attributed to a possible 
cancer stem-cell lineage present in the tumor bulk [29, 30].
Cancer stem-cell has awaked interest in the context of breast cancer because of 
its characteristic heterogeneity of biological behavior and therapeutic response. It 
has been hypothesized that cancer stem-cell might be one of the causes of the high 
variability of biological and prognostic spectrum of breast cancer. Cancer-stem 
cells might play an important role on therapeutic resistance and progression of 
disease, affecting the overall and free of disease survival [31, 32].
Thus, an important feature which allows possible cancer stem-cell resistance to 
chemotherapy is its low expression of surface proteins. Because of its self-renewal 
properties, cancer stem-cell does not depends on signaling from other cells to 
proceed its functions in tumoral tissues. Furthermore, for its low antigenicity 
and low proliferation index, there are few alternatives for drug interactions. DNA 
damage agents are poor effective against these cells possibly for a lack of prolifera-
tion, as well new classes of drugs, like PARP inhibitors, which better act on cells in 
proliferative phase [31, 33].
One of possible pathways for breast cancer therapeutic resistance acquired along 
the time might be explained by populations of cancer stem-cells not eliminated, 
selected by multiple chemotherapy cycles. Tumoral cells in active proliferation 
phase are more hitten, increasing the proportion of indolent cells with stem-like 
features in cancer cell population. Through the capacity of multilineage differentia-
tion, cancer stem cells might generate new daughter cells with more aggressiveness 
and chemoresistance [32, 34].
The identification of cancer stem-cells is challenging. First, because of its irregu-
lar distribution in selected tumor amounts. Second, for definition, these cells are 
frequently scarces in tumor bulk. In this way, these cells are better identified through 
“in vitro” methods, like cellular cultures. However, the mainly disadvantage of this 
technique is the fact of stem cells behave in a different fashion in artificial environ-
ment, since the cell phenotype expression depends on their interactions [32, 35].
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Thus, several studies with cancer stem-cells in different neoplastic tissues have 
been accomplished with conflicting results. An interesting method to identify these 
cells in their original environment is the immunohistochemistry performed on 
amounts of paraffin-embedded neoplastic tissues, with the advantages to allow the 
evaluation of phenotype expression next to the reality and to be easily performed 
and cost-effectiveness in diagnostic routine [35].
In the last years, some putative stem-cell markers detected by immunohisto-
chemistry have been tested in paraffinized tissues of breast cancer. Multiple studies 
have demonstrated that expression of putative stem-cell markers by tumoral cells 
seems to worse the prognosis and survival in breast cancer. The most frequent 
studied stem-cell markers are CD24, CD44, CD133 and EPCAM, with two identi-
fied putative stem-cell phenotypes: CD24 low/CD44 enriched and co-expression of 
CD133 and EPCAM (Figure 4). Besides of the scarcity of stem-cells in neoplastic 
tissues, the conflictous results of these studies might be explained by a neces-
sity to qualitative analysis of these markers expression, exactly for the rarity of 
stem-cells [32, 36].
In some studies, identification of a stem-cell like phenotype CD24 low/CD44 
enriched have prejudiced the free of disease survival, especially in cases of early 
stages of breast cancer, with more occurrence of distant metastasis and cancer 
recurrence after surgical and adjuvant treatments. The presence of cancer cells with 
positivity for cancer stem-cell phenotype CD133/EPCAM is has been related to poor 
overall survival in breast cancer, with more adjuvant therapeutic fail [32].
For the moment, these putative stem-cell phenotypes seems to be independent 
prognostic factors in breast cancer. “Triple negative” breast cancer and BRCA-1 
mutant breast cancer have been associated to stem-cell like phenotype CD24 
low/CD44 enriched. These putative stem-cell markers may become possible future 
targets for new drugs in the future [30, 32].
Figure 4. 
Photomicrographies of double-labeled simple stained putative CSC antibodies (400×, original magnification, 
immunoperoxidase and DAB). (A) CD133: cytoplasm positivity (immunoperoxidase); (B) EPCAM: 
membrane positivity (DAB); (B) CD133+/EPCAM+: CSC profile (black arrow: membrane positivity to 
DAB and cytoplasm positivity to immunoperoxidase at the same cell); (C) CD24: cytoplasm positivity 
(immunoperoxidase); (D) CD24−/CD44+: CSC profile (black arrow: membrane positivity only to DAB)
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5. Immunologic aspects related to breast cancer
In the context of cancer, the immune system can suppress the tumor growth by 
the destruction of cancer cells or inhibition of their outgrowth. On the other hand, 
immune system can play a role on tumor progression by the selection of tumor cells 
which are adapted to survive in an immunocompetent host or modifying the tumor 
environment to facilite the tumor outgrowth [37] .
Elevated levels of CD4+ regulatory T lymphocytes (Tregs) found in many 
cancers are associated to poor prognosis. Tregs create a favorable immunosuppres-
sive microenvironment to the outgrowth and progression of the tumor. On this way, 
FOXP3 is expressed by the Tregs and can be detected by immunohistochemistry. 
FOXP3 is responsible for induction and maintenance of tolerance to self antigens 
in normal cells, as well this immunotolerance can be performed by the Tregs with 
cancer cell antigens [37, 38].
Another example of cancer cell escape mechanism from the immune system 
is caspase-8 mutations present in “triple negative” breast cancers and other solid 
malignant tumors. These mutations abolish the death induced by cytotoxic lympho-
cytes CD8+ in tumoral cells [37, 39].
The activation of T lymphocytes by foreign antigens occurs by concomitant 
major histocompatibility complex (MHC) antigen presentation and co-expression of 
T-cell receptor (TCR). At the same time, a family of T-cell transmembrane proteins 
CD28/B7, called “immune checkpoints”, produces co-inhibitory or co-stimulatory 
signals. The immune checkpoints regulates the T-cell immunotolerance to protect 
the tissues from undesirable damages. Cancer cells may produce signals to inhibit 
T-cell action, through cytotoxic T-lymphocyte associated antigen-4 (CTLA-4), 
programmed cell death-1 (PD-1) and its ligands (PDL-1) [37, 40].
PD-1 is an inhibitory “immune checkpoint” expressed on the surface of T-cells, 
B-cells and NK-cells. When T-cells have been activated by their TCR, the cells 
express at the same time PD-1, which is a possibility to the attacked cell to escape 
from the immune reaction (Figure 5). Cancer cells express the ligand PDL-1 on 
their surfaces, activating PD-1 of T-cells, escaping from the attack [37, 40].
PD-L1 expression has been associated with large tumor size, high grade, high 
proliferation, estrogen receptor (ER)-negative status, and human epidermal 
growth factor receptor-2 (HER2)-positive status in breast cancer. Survival in breast 
cancer is inversely related to PD-1/PDL-1 levels. PDL-1 expression increases tumor 
Figure 5. 
Simplified schematic illustration of PD-1/PDL-1 interactions in immune responses against cancer cell. Tumoral 
antigens (Ag) are presented via T-cell by major histocompatibility complex (MHC) of dendritic cells. T-cell 
recognize tumoral Ag via TCR (T-cell receptor). Interaction Ag-TCR induces an positive immune response against 
tumoral Ag. Though, there is a scape mechanism of cancer cell from the T-cell attack: interaction of programmed 
death cell ligands (PDL-1/2) expressed by cancer cell with PD-1 expressed by T-cell inhibit the T-cell action. 
This scape mechanism of cancer cell mimics the regulation action to avoid immune responses of T-cell against self 
antigens. The principle of immune therapy is the inhibition of PD-1/PDL-1 (extracted from [40]).
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aggressiveness, stimulating tumorigenesis, invasiveness and ability to escape from 
cytotoxic T CD8+ lymphocytes attacks [39, 41]. The immunohistochemical evalua-
tion of PDL-1 is shown in Figure 6.
Immune therapies with anti-CTLA-4 and anti-PD1/anti-PDL-1 agents have been 
promising for treating several cancers. In breast cancer, some researches reported 
positive results around 20% of breast tumors on treatment with these agents, 
mainly the “triple negative” and HER-2 subtypes, for their higher antigenicity. In 
general, breast cancer present lower immunogenicity than other cancers and breast 
cancer cells frequently create an immunosuppressor tumor microenvironment by 
signaling [37, 43].
The presence of tumor infiltrating lymphocytes (TIL) in some breast cancers 
has been related to a favorable prognosis, especially in “triple negative” and HER-2 
subtypes. TIL are formed mainly by T-cells CD3+/CD56 negative, which are either 
CD4+ or CD8+. A minority component of B-cells CD20+ and NK-cells may be pres-
ent. The attraction of TIL by cancer cells have been related to their expression of 
some chemokines, like CXCL9 and CXCL13 [37, 44].
In “triple negative” and HER-2 subtypes of breast cancer, the presence of 
TIL is related to a better response to neoadjuvant therapy, as well neoadjuvant 
treatment may modify the tumor microenvironment to attract TIL to tumor site. 
Furthermore, when the TIL are not attracted instead of neoadjuvance, it is indica-
tive for bad prognosis [44].
Figure 6. 
Examples of PDL-1 expression in breast cancer using 3 different antibodies: Dako 22C3 (D,E and F), Ventana 
SP263 (G,H and I) and BioCare RbM CAL10 (A, B and C). PDL-1 scoring is divided into 3 groups: zero 
staining is negative, 1–49% of positive cells are considered “low PDL-1 expression” and 50% of more positive 
cells are considered “high PDL-1 expression”. Examples of negative, low and high PDL-1 expression are 
represented on A, B and C for BioCare antibody (extracted from [42]).
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6.  Advanced stage breast cancer: considerations under current approach 
and futures perspectives
Metastatic breast cancer is considered incurable nowadays with currently 
therapies. Therapy of metastatic disease aims to guarantee quality of life, pallia-
tion of symptoms and prolongation of the patient survival. Advanced stage disease 
is becoming increasingly chronic, controlled by sequencial therapies, with more 
personalized approach than the early stage breast cancer [8].
Systemic therapy is frequently the first choice of metastatic disease. Before the 
new therapeutic decision, it is necessary to consider the previous treatments. If 
possible, it is recommended to re-evaluate the histologic features and molecular 
subtype status of the metastatic lesion through a new biopsy, with new immu-
nohistochemical study for hormonal receptor and HER-2 status. Some studies 
reported until 40% of discrepances of metastatic lesion histologic features and 
molecular subtype status versus primary tumor histologic and immunohistochemi-
cal aspects [45].
The metastatic disease therapeutic choices search for positive targets to hit 
more effectively the neoplastic cells. Thereby, expression of hormonal receptors 
by the metastatic lesion is elective for endocrine therapy. Endocrine drugs include 
tamoxifen, aromatase inhibitors, fulvestrant and progestins. The use of these drugs 
in metastasis with hormone receptor positive status have demonstrated increase of 
free of disease survival in several studies [8, 45].
Furthermore, new generation of drugs which inhibit the cyclin dependant kinase 
(CDK) have been successful in prolongation of free of disease survival in luminal 
subtype HER-2 negative metastatic disease. CDK4/6 is a holoenzyme responsible for 
several extracellular signaling pathways to cell cycle transitions. CDK4/6 fosforilates 
and inactivates retinoblastoma tumor supressor protein (Rb). Extracellular signals 
regulate the expression of cyclins and CDK inhibitors, like p16INK4a [46].
In human cancer, this circuit is dysregulated by either overexpression of cyclin 
D1, loss of p16Ink4a, the mutation of CDK4 to an Ink4-refractory state, or the loss of 
Rb itself. The primary target of CDK4 is the Rb protein, though this holoenzyme 
either can phosphorylate factors involved in cell differentiation affecting their 
transcriptional activity, apoptotic factors affecting their activity and other factors 
that can directly affect mitochondrial function [8, 46, 47].
Therefore, CDK inhibitors act in tumor microenvironment, blocking Rb 
phosphorilation and leading to cell cycle exit. Moreover, CDK have kinase activity 
towards SPOP, an ubiquitin protein that interacts with PDL-1. CDK inhibitors lead 
to inhibition of SPOP phosphorilation with blockade of PDL-1 and stimulus to 
PD-1 expression by T-cells, attracting T-cell infiltration to the tumor. In this way, 
the combined use of CDK inhibitors and PDL-1/PD-1 inhibitors may be promising, 
requiring more future studies [46–48].
For the moment, hormonal receptors and HER-2 status are the few validated 
molecular targets of clinical importance on metastatic breast cancer approach-
ing through chemotherapy and endocrine therapy. For HER-2 positive metastatic 
disease, anti-HER-2 treatment with trastuzumab is well established and is recom-
mended as soon as possible. Immune therapy is not standardized for metastatic 
breast cancer, since metastatic breast disease is highly heterogeneous. Though, it 
is a promising therapy for the future, as well the target molecular therapies, which 
become more effective with discovery of novel pathways and mutations by new 
studies to be developed [8].
A resume of main biomarkers of clinicopathologic importance for breast cancer 
management is shown in Table 3 and a proposal of a algorithm for clinicopathologic 
evaluation of breast cancer is presented in Table 4.
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IHC1/FISH Biomarkers of molecular 
subtypes of breast cancer
Targets for endocrine and anti-




Biomarker of hereditary 
breast cancer
Target for PARP inhibitors; 
indication for other 
malignancies screening
CD24, CD44, CD133, 
EPCAM
IHC Putative stem-cell 
biomarkers
Prediction of poor prognosis, 
risk of tumor progression and 
reduction of survival
PD-1/PDL-1 IHC Biomarker of possible 
inhibited immune response 
of T-cell against cancer cell





Marker of better cellular 
mediated immune 
response against cancer cell
Prediction of better 
therapeutic responses, mainly 
of neoadjuvant therapies
1IHC = Immunohistochemistry.
2TILs = Tumoral infiltrating lymphocytes.
Table 3. 
Resume of main biomarkers of clinicopathologic importance for breast cancer management.
Table 4. 
Proposal of an algorithm for clinicopathologic evaluation of breast cancer.
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7. Conclusion and final considerations
In the 21st century, breast cancer classification and diagnosis advanced consider-
ably from a purely morphologic/histologic approaching to a immune and molecular 
basis, with remarkable improvement of the correlation between classification and 
prediction of biological behavior and prognosis.
The adoption of a clinicopathologic classification based on molecular subtypes 
of breast cancer in the last decade has modified decisively the management of the 
disease in the way of molecular era, opening new ways to discovering of multiple 
targets for novel therapies.
Innovative concepts related to immune reactions related to human cancers, 
which have been unveiled in the recent years, particularly the immune checkpoints, 
have offered new treatment tools for several human cancers with promising 
results, although not still established for breast cancer.
In the molecular era of cancer, the integration of novel knowledges in a direction 
of more accurated diagnosis and prediction of prognosis to allow personalized ther-
apies is the key to future human cancer management, including the breast cancer.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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